Neuro-immune abnormalities in autism and their relationship with the environment: A variable insult model for autism

Frontiers in Endocrinology

Volumn 5, Issue MAR, 2014, Pages

  Goyal, Daniel K ^a   Miyan, Jaleel A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Autism spectrum disorder; Environment; Gut microbiota; Neuro immune; Neuroinflammation

Indexed keywords

MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1;

AUTISM; AUTONOMIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL IMPACT; EXPERIMENTAL MODEL; GENETIC HETEROGENEITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INTESTINE FLORA; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; REVIEW; SOCIALIZATION;

EID: 84901060888     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00029     Document Type: Review

References (98)

1. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry (2011) 76:v1. doi:10.1001/archgenpsychiatry.2011.76.
2. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol (2005) 57(1):67-81. doi:10.1002/ana.20315.
3. Suzuki K, Sugihara G, Ouchi Y, Nakamura K, Futatsubashi M, Takebayashi K, et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry (2013) 70(1):49-58. doi:10.1001/jamapsychiatry.2013.272.
4. Tetreault NA, Hakeem AY, Jiang S, Williams BA, Allman E, Wold BJ, et al. Microglia in the cerebral cortex in autism. J Autism Dev Disord (2012) 42(12):2569-84. doi:10.1007/s10803-012-1513-0.
5. Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry (2010) 68(4):368-76. doi:10.1016/j.biopsych.2010.05.024.
6. Coleman M. Clinical review: medical differential diagnosis and treatment of the autistic syndrome. Eur Child Adolesc Psychiatry (1993) 2(3):161-8. doi:10.1007/BF02125571.
7. Steffenburg S. Neuropsychiatric assessment of children with autism: a population based study. Dev Med Child Neurol (1991) 33(6):495-511. doi:10.1111/j.1469-8749.1991.tb14915.x.
8. Lawler CP. The environmental for autism research: signs of improvement? Environ Health Perspect (2008) 116(10):A416. doi:10.1289/ehp.12107.
9. Interagency Autism Coordinating Committee. 2011 IACC Strategic Plan for Autism Spectrum Disorder Research. Washington, DC: US Department of Health and Human Services (2011).
10. Combating Autism Act, US Public Law 109-416 (2006).
11. Coleman M, Gillberg C. The Autisms. New York: Oxford University Press (2012).
12. Kanner L. Autistic disturbances of affective contact. Nervous child (1943) 2(3):217-50.
13. Kanner L. Problems of nosology and psychodynamics of early infantile autism. Am J Orthopsychiatry (1949) 19(3):416-26. doi:10.1111/j.1939-0025.1949.tb05441.x.
14. Kanner L. Follow-up study of eleven autistic children originally reported in 1943. J Autism Dev Disord (1971) 1(2):119-45. doi:10.1007/BF01537953.
15. Seltzer MM, Shattuck P, Abbeduto L, Greenberg JS. Trajectory of development in adolescents and adults with autism. Ment Retard Dev Disabil Res Rev (2004) 10:234-47. doi:10.1002/mrdd.20038.
16. Lotter V. Epidemiology of autistic conditions in young children: 1. Prevalence. Soc Psychiatry (1966) 1:124-37. doi:10.1007/BF00584048.
17. Kuehn BM. CDC: autism spectrum disorders common. JAMA (2007) 297(9):940-940. doi:10.1001/jama.297.9.940.
18. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators, Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, 14 sites, United States, 2008. MMWR Surveill Summ (2012) 61(3):1-19.
19. Baron-Cohen S, Scott FJ, Allison C, Williams J, Bolton P, Matthews FE, et al. Prevalence of autism-spectrum conditions: UK school-based population study. Br J Psychiatry (2009) 194(6):500-9. doi:10.1192/bjp.bp.108.059345.
20. Shavelle RM, Strauss DJ, Pickett J. Causes of death in autism. J Autism Dev Disord (2001) 31(6):569-76. doi:10.1023/A:1013247011483.
21. Gillberg C, Billstedt E, Sundh V, Gillberg IC. Mortality in autism: a prospective longitudinal community-based study. J Autism Dev Disord (2010) 40(3):352-7. doi:10.1007/s10803-009-0883-4.
22. Mouridsen SE, Brønnum-Hansen H, Rich B, Isager T. Mortality and causes of death in autism spectrum disorders. Autism (2008) 12(4):403-14. doi:10.1177/1362361308091653.
23. Turner LM, Stone WL. Variability in outcome for children with an ASD diagnosis at age 2. J Child Psychol Psychiatry (2007) 48(8):793-802. doi:10.1111/j.1469-7610.2007.01744.x.
24. Levy A, Perry A. Outcomes in adolescents and adults with autism: a review of the literature. Res Autism Spectr Disord (2011) 5(4):1271-82. doi:10.1016/j.rasd.2011.01.023.
25. Newschaffer CJ, Croen LA, Daniels J, Giarelli E, Grether JK, Levy SE, et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health (2007) 28:235-58.
26. Schendel DE, Diguiseppi C, Croen LA, Fallin MD, Reed PL, Schieve LA, et al. The study to explore early development (SEED): a multisite epidemiologic study of autism by the Centres for Autism and Developmental Disabilities Research and Epidemiology (CADDRE) Network. J Autism Dev Disord (2012) 42:1-20. doi:10.1007/s10803-012-1461-8.
27. Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry (2005) 17(6):485-95. doi:10.1080/02646830500381930.
28. Ashwood P, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen RL, Croen LA, et al. Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol (2008) 204(12):149-53. doi:10.1016/j.jneuroim.2008.07.006.
29. Enstrom AM, Lit L, Onore CE, Gregg JP, Hansen RL, Pessah IN, et al. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun (2009) 23(1):124-33. doi:10.1016/j.bbi.2008.08.001.
30. Dalziel SR, Thompson JM, Macias CG, Fernandes RM, Johnson DW, Waisman Y, et al. Predictors of severe H1N1 infection in children presenting within Pediatric Emergency Research Networks (PERN): retrospective case-control study. BMJ (2013) 347:f4836. doi:10.1136/bmj.f4836.
31. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van deWater J. Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J Neuroimmunol (2011) 232(1):196-9. doi:10.1016/j.jneuroim.2010.10.025.
32. Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol (2007) 17:434-47. doi:10.1111/j.1750-3639.2007.00102.x.
33. Herbert MR. Large brains in autism: the challenge of pervasive abnormality. Neuroscientist (2005) 11:417-40. doi:10.1177/0091270005278866.
34. Hallahan B, Daly EM, McAlonan G, Loth E, Toal F, O'Brien F, et al. Brain morphometry volume in autistic spectrum disorder: a magnetic resonance imaging study of adults. Psychol Med (2009) 39(02):337-46. doi:10.1017/S0033291708003383.
35. Casanova M, Buxhoeveden D, Switala A, Roy E. Minicolumnar pathology in autism. Neurology (2002) 58(3):428-32. doi:10.1212/WNL.58.3.428.
36. Casanova MF. The significance of minicolumnar size variability in autism: a perspective from comparative anatomy. In: Zimmerman AW, editor. Autism. Totowa, NJ: Humana Press (2008) p. 349-60. doi:10.1007/978-1-60327-489-0_16.
37. Minshew NJ, Payton JB. New perspectives in autism, Part II: the differential diagnosis and neurobiology of autism. Curr Probl Pediatr (1988) 18:613-94. doi:10.1016/0045-9380(88)90017-5.
38. Minshew NJ, Williams DL. The new neurobiology of autism. Arch Neurol (2007) 64:945-50. doi:10.1001/archneur.64.7.945.
39. Baird AD, Scheffer IE, Wilson SJ. Mirror neuron system involvement in empathy: a critical look at the evidence. Soc Neurosci (2011) 6(4):327-35. doi:10.1080/17470919.2010.547085.
40. Gowen E, Hamilton A. Motor abilities in autism: a review using a computational context. J Autism Dev Disord (2013) 43(2):323-44. doi:10.1007/s10803-012-1574-0.
41. Gowen E. Imitation in autism: why action kinematics matter. Front Integr Neurosci (2012) 6:117. doi:10.3389/fnint.2012.00117.
42. Hutt C, Forrest SJ, Richer J. Cardiac arrhythmia and behaviour in autistic children. Acta Psychiatr Scand (1975) 51(5):361-72. doi:10.1111/j.1600-0447.1975.tb00014.x.
43. Kootz JP, Cohen DJ. Modulation of sensory intake in autistic children: cardiovascular and behavioral indices. J Am Acad Child Psychiatry (1981) 20(4):692-701. doi:10.1097/00004583-198102000-00002.
44. Kootz JP, Marinelli B, Cohen DJ. Modulation of response to environmental stimulation in autistic children. J Autism Dev Disord (1982) 12(2):185-93. doi:10.1007/BF01531308.
45. Zahn TP, Rumsey JM, Van Kammen DP. Autonomic nervous system activity in autistic, schizophrenic, and normal men: effects of stimulus significance. J Abnorm Psychol (1987) 96(2):135. doi:10.1037/0021-843X.96.2.135.
46. James AL, Barry RJ. Respiratory and vascular responses to simple visual stimuli in autistics, retardates and normals. Psychophysiology (1980) 17(6):541-7. doi:10.1111/j.1469-8986.1980.tb02294.x.
47. Cohen DJ, Johnson WT. Cardiovascular correlates of attention in normal and psychiatrically disturbed children: blood pressure, peripheral blood flow, and peripheral vascular resistance. Arch Gen Psychiatry (1977) 34(5):561. doi:10.1001/archpsyc.1977.01770170071006.
48. Palkovitz RJ, Wiesenfeld AR. Differential autonomic responses of autistic and normal children. J Autism Dev Disord (1980) 10(3):347-60. doi:10.1007/BF02408294.
49. Ming X, Julu PO, Brimacombe M, Connor S, Daniels ML. Reduced cardiac parasympathetic activity in children with autism. Brain Dev (2005) 27(7):509-16. doi:10.1016/j.braindev.2005.01.003.
50. Field T, Diego M. Vagal activity, early growth and emotional development. Infant Behav Dev (2008) 31(3):361-73. doi:10.1016/j.infbeh.2007.12.008.
51. Kushki A, Drumm E, Pla Mobarak M, Tanel N, Dupuis A, Chau T, et al. Investigating the autonomic nervous system response to anxiety in children with autism spectrum disorders. PLoS One (2013) 8(4):e59730. doi:10.1371/journal.pone.0059730.
52. James AL, Barry RJ. Cardiovascular and electrodermal responses to simple stimuli in autistic, retarded and normal children. Int J Psychophysiol (1984) 1(2):179-93. doi:10.1016/0167-8760(84)90037-0.
53. Gogtay N, Giedd JN, Lusk L, Hayashi KM, Greenstein D, Vaituzis AC, et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A (2004) 101(21):8174. doi:10.1073/pnas.0402680101.
54. Hertz-Picciotto I, Park HY, Dostal M, Kocan A, Trnovec T, Sram R. Prenatal exposures to persistent and non-persistent organic compounds and effects on immune system development. Basic Clin Pharmacol Toxicol (2008) 102(2):146-54. doi:10.1111/j.1742-7843.2007.00190.x.
55. West LJ. Defining critical windows in the development of the human immune system. Hum Exp Toxicol (2002) 21:499-505. doi:10.1191/0960327102ht288oa.
56. Volk HE, Hertz-Picciotto I, Delwiche L, Lurmann F, McConnell R. Residential proximity to freeways and autism in the CHARGE study. Environ Health Perspect (2011) 119(6):873. doi:10.1289/ehp.1002835.
57. Hertz-Picciotto I, Bergman A, Fängström B, Rose M, Krakowiak P, Pessah I, et al. Polybrominated diphenyl ethers in relation to autism and developmental delay: a case-control study. Environ Health (2011) 10:1. doi:10.1186/1476-069X-10-1.
58. Toms LM, Sjödin A, Harden F, Hobson P, Jones R, Edenfield E, et al. Serum polybrominated diphenyl ether (PBDE) levels are higher in children (25 years of age) than in infants and adults. Environ Health Perspect (2009) 117(9):1461. doi:10.1289/ehp.0900596.
59. Roberts EM, English PB, Grether JK, Windham GC, Somberg L, WolffC. Maternal residence near agricultural pesticide applications and autism spectrum disorders among children in the California Central Valley. Environ Health Perspect (2007) 115(10):1482. doi:10.1289/ehp.10168.
60. Eskenazi B, Rosas LG, Marks AR, Bradman A, Harley K, Holland N, et al. Pesticide toxicity and the developing brain. Basic Clin Pharmacol Toxicol (2008) 102(2):228-36. doi:10.1111/j.1742-7843.2007.00171.x.
61. Rosas LG, Eskenazi B. Pesticides and child neurodevelopment. Curr Opin Pediatr (2008) 20(2):191. doi:10.1097/MOP.0b013e3282f60a7d.
62. Dietert RR, Dietert JM. Potential for early-life immune insult including developmental immunotoxicity in autism and autism spectrum disorders: focus on critical windows of immune vulnerability. J Toxicol Environ Health B Crit Rev (2008) 11(8):660-80. doi:10.1080/10937400802370923.
63. Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis (2002) 35(Suppl 1):S6-16. doi:10.1086/341914.
64. Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol (2004) 70(11):6459-65. doi:10.1128/AEM.70.11.6459-6465.2004.
65. Parracho HM, Bingham MO, Gibson GR, McCartney AL. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol (2005) 54(10):987-91. doi:10.1099/jmm.0.46101-0.
66. Williams BL, Hornig M, Buie T, Bauman ML, Cho Paik M, Wick I, et al. Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances. PLoS One (2011) 6(9):e24585. doi:10.1371/journal.pone.0024585.
67. Martirosian G, Ekiel A, Aptekorz M, Wiechula B, Kazek B, Jankowska-Steifer E, et al. Fecal lactoferrin and Clostridium spp. in stools of autistic children. Anaerobe (2011) 17(1):43-5. doi:10.1016/j.anaerobe.2010.12.003.
68. Bolte ER. Autism and Clostridium tetani. Med Hypotheses (1998) 51(2):133-44. doi:10.1016/S0306-9877(98)90107-4.
69. Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Väisänen ML, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol (2000) 15(7):429-35. doi:10.1177/088307380001500701.
70. Noverr MC, Huffnagle GB. Review: the 'microflora hypothesis' of allergic diseases. Clin Exp Allergy (2005) 35(12):1511-20. doi:10.1111/j.1365-2222.2005.02379.x.
71. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol (2009) 9:313-23. doi:10.1038/nri2515.
72. Jyonouchi H, Geng L, Streck DL, Toruner GA. Children with autism spectrum disorders (ASD) who exhibit chronic gastrointestinal (GI) symptoms and marked fluctuation of behavioral symptoms exhibit distinct innate immune abnormalities and transcriptional profiles of peripheral blood (PB) monocytes. J Neuroimmunol (2011) 238(1-2):73-80. doi:10.1016/j.jneuroim.2011.07.001.
73. Jyonouchi H, Geng L, Ruby A, Reddy C, Zimmerman-Bier B. Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr (2005) 146(5):605-10. doi:10.1016/j.jpeds.2005.01.027.
74. Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology (2005) 51(2):77-85. doi:10.1159/000084164.
75. Goines PE, Ashwood P. Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment. Neurotoxicol Teratol (2013) 36:67-81. doi:10.1016/j.ntt.2012.07.006.
76. Unwin LM, Maybery MT, Wray JA, Whitehouse AJO. A "bottom-up" approach to aetiological research in autism spectrum disorders. Front Hum Neurosci (2013) 7:606. doi:10.3389/fnhum.2013.00606.
77. Tian Y, Green PG, Stamova B, Hertz-Picciotto I, Pessah IN, Hansen R, et al. Correlations of gene expression with blood lead levels in children with autism compared to typically developing controls. Neurotox Res (2011) 19(1):1-13. doi:10.1007/s12640-009-9126-x.
78. Stamova B, Green PG, Tian Y, Hertz-Picciotto I, Pessah IN, Hansen R, et al. Correlations between gene expression and mercury levels in blood of boys with and without autism. Neurotox Res (2011) 19(1):31-48. doi:10.1007/s12640-009-9137-7.
79. Kamila M, Markram H. The intense world theory-a unifying theory of the neurobiology of autism. Front Hum Neurosci (2010) 4:224. doi:10.3389/fnhum.2010.00224.
80. Reynolds S, Millette A, Devine DP. Sensory and motor characterization in the postnatal valproate rat model of autism. Dev Neurosci (2012) 34:258-67. doi:10.1159/000336646.
81. Finegold Sydney M, Downes J, Summanen PH. Microbiology of regressive autism. Anaerobe (2012) 18(2):260-2. doi:10.1016/j.anaerobe.2011.12.018.
82. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell (2006) 124(4):837-48. doi:10.1016/j.cell.2006.02.017.
83. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol (2007) 5:e177. doi:10.1371/journal.pbio.0050177.
84. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun (2012) 26(3):383-92. doi:10.1016/j.bbi.2011.08.007.
85. Schieve LA, Gonzalez V, Boulet SL, Visser SN, Rice CE, Van Naarden Braun K, et al. Concurrent medical conditions and health care use and needs among children with learning and behavioral developmental disabilities, National Health Interview Survey, 2006-2010. Res Dev Disabil (2012) 33(2):467-76. doi:10.1016/j.ridd.2011.10.008.
86. Kohane IS, McMurry A, Weber G, MacFadden D, Rappaport L, Kunkel L, et al. The comorbidity burden of children and young adults with autism spectrum disorders. PLoS One (2012) 7(4):e33224. doi:10.1371/journal.pone.0033224.
87. Buie T, Fuchs GJ III, Furuta GT, Kooros K, Levy J, Lewis JD, et al. Recommendations for evaluation and treatment of common gastrointestinal problems in children with ASDs. Pediatrics (2010) 125(Suppl 1):S19-29. doi:10.1542/peds.2009-1878D.
88. Buie T, Campbell DB, Fuchs GJ III, Furuta GT, Levy J, Van de Water J, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics (2010) 125(Suppl 1):S1-18. doi:10.1542/peds.2009-1878C.
89. Iwata Y, Tsuchiya KJ, Mikawa S, Nakamura K, Takai Y, Suda S, et al. Serum levels of P-selectin in men with high-functioning autism. Br J Psychiatry (2008) 193:338-9. doi:10.1192/bjp.bp.107.043497.
90. Heuer L, Ashwood P, Schauer J, Goines P, Krakowiak P, Hertz-Picciotto I, et al. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res (2008) 1:275-83. doi:10.1002/aur.42.
91. Grigorenko EL, Han SS, Yrigollen CM, Leng L, Mizue Y, Anderson GM, et al. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics (2008) 122:e438-45. doi:10.1542/peds.2007-3604.
92. Onore C, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen R, Van de Water J, et al. Decreased cellular IL-23 but not IL-17 production in children with autism spectrum disorders. J Neuroimmunol (2009) 216:126-34. doi:10.1016/j.jneuroim.2009.09.005.
93. Enstrom AM, Onore CE, Van de Water JA, Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun (2010) 24:64-71. doi:10.1016/j.bbi.2009.08.001.
94. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J. Altered T cell responses in children with autism. Brain Behav Immun (2010) 25(5):840-9. doi:10.1016/j.bbi.2010.09.002.
95. Goines P, Haapanen L, Boyce R, Duncanson P, Braunschweig D, Delwiche L, et al. Autoantibodies to cerebellum in children with autism associate with behavior. Brain Behav Immun (2011) 25:514-23. doi:10.1016/j.bbi.2010.11.017.
96. Kajizuka M, Miyachi T, Matsuzaki H, Iwata K, Shinmura C, Suzuki K, et al. Serum levels of platelet-derived growth factor BB homodimers are increased in male children with autism. Prog Neuropsychopharmacol Biol Psychiatry (2010) 34:154-8. doi:10.1016/j.pnpbp.2009.10.017.
97. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun (2011) 25:40-45. doi:10.1016/j.bbi.2010.08.003.
98. Ross HE, Guo Y, Coleman K, Ousley O, Miller AH. Association of IL-12p70 and IL-6:IL-10 ratio with autism-related behaviors in 22q11.2 deletion syndrome: a preliminary report. Brain Behav Immun (2013) 31:76-81. doi:10.1016/j.bbi.2012.12.021.